Navigation Links
Duska Therapeutics Provides Program Update and Reports Third Quarter 2008 Financial Results
Date:11/20/2008

LA JOLLA, Calif., Nov. 20 /PRNewswire-FirstCall/ -- Duska Therapeutics, Inc. (OTC Bulletin Board: DSKA) will host a teleconference call today at 2:30 p.m. EST to review its drug development programs and financial results for the third quarter of 2008. Duska's chief executive officer, James S. Kuo, MD, MBA, will host the call and there will be a question-and-answer session immediately afterward.

To participate in the teleconference, please call toll-free 800.895.0198 (direct dial 785.424.1053) five minutes prior to the scheduled starting time in order to register for the call. A replay of the call will be available after its completion for ten days at 800.283.8217 (direct dial 402.220.0868).

"We have made remarkable progress in our two lead drug development programs this past quarter as we prepare for a Phase 2 trial for one compound and a Phase 3 trial for the other early next year," said Dr. Kuo. "In addition, we strengthened the intellectual property position around our ATPotent program through licenses with several inventors."

    Highlights of accomplishments included:

    -- Submission of a pivotal Phase 3 ATPace clinical trial protocol for
       review under a Special Protocol Assessment (SPA) procedure with the
       U.S. Food and Drug Administration (FDA).

       Subject to securing an agreement with the FDA, Duska intends to
       initiate a single, prospective, double-blind, placebo-controlled and
       randomized Phase 3 clinical trial with ATPace, its lead product. The
       trial will be aimed at demonstrating clinical safety and efficacy of
       ATPace in treating emergency room patients presenting with paroxysmal
       supraventricular tachycardia (PSVT).  PSVT is a condition characterized
       by a rapid, regular heart rate originating in the atria, which affects
       approximately 570,000 patients in the United States alone; in addition,
       89,000 new cases per 
'/>"/>
SOURCE Duska Therapeutics, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related biology technology :

1. Leading Heart Specialist Joins Duska Therapeutics as Scientific Consultant
2. Duska Therapeutics to Present at Noble Financial Equity M.A.D. MAX Conference on Tuesday, August 19th at 1:30 p.m. PDT
3. Duska Therapeutics Submits Phase 3 ATPace(TM) Protocol to FDA for Comment
4. Duska Therapeutics Obtains Standard & Poors Listing
5. Synvista Therapeutics Announces 510(k) Submission for Its HAPTOCHEK(TM) Test Kit
6. Arete Therapeutics Closes $16.7 Million in Final Tranche of Its Series A Financing
7. TorreyPines Therapeutics Appoints Evelyn Graham Chief Executive Officer and a Member of the Board of Directors
8. TorreyPines Therapeutics Reports Third Quarter 2008 Results and Recent Accomplishments
9. Synvista Therapeutics Announces Data Further Demonstrating the Value of Haptoglobin Genotyping in Diabetic Patients During AHA Meeting
10. Amicus Therapeutics to Present at Lazard Capital Markets Healthcare Conference
11. Synvista Therapeutics to Present at the Rodman & Renshaw 10th Annual Healthcare Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/20/2014)... 2014 Earle Martin , ... today that Ellen Teplitzky, an experienced attorney specializing ... pharmaceutical industry, has joined the firm as Director ... services practice. NDA Partners provides legal services, ... testimony, to top law firms and their clients ...
(Date:10/19/2014)... 2014 OCTOBER 20-22, 2014: ... ABIM will take place at the ... ABIM 2014 is now available at ... companies and organizations from all over the ... on the latest products and developments on ...
(Date:10/19/2014)... The Asian Automatic patient billing report defines ... forecast of revenue. The Automatic patient billing market in ... by 2018, at a developing CAGR of 7.2% from ... the Asian Automatic patient billing market, to get an ... a glimpse of the segmentation of this market in ...
(Date:10/19/2014)... The Asian Orthopedic braces and support systems report defines ... forecast of revenue. The Orthopedic braces and support systems market ... by 2018, at a developing CAGR of 4.4% from 2013 ... Orthopedic braces and support systems market, to get an idea ... of the segmentation of orthopedic braces and support systems market ...
Breaking Biology Technology:NDA Partners Appoints Ellen Teplitzky, JD as Director of its Legal Services Practice 2The Asian Automatic patient billing market is estimated to grow to around $463.9 million by 2018 - New Report by MicroMarket Monitor 2The Asian Automatic patient billing market is estimated to grow to around $463.9 million by 2018 - New Report by MicroMarket Monitor 3The Asian Orthopedic braces and support systems market is estimated to grow to around $416.5 million by 2018 - New Report by MicroMarket Monitor 2The Asian Orthopedic braces and support systems market is estimated to grow to around $416.5 million by 2018 - New Report by MicroMarket Monitor 3The Asian Orthopedic braces and support systems market is estimated to grow to around $416.5 million by 2018 - New Report by MicroMarket Monitor 4
... Calif., Oct. 19, 2011 Process automation specialist Endress+Hauser ... company that develops, produces and distributes sensors, hardware and ... to strengthen its position in the area of biotechnology ... important role in the future, not only in the ...
... Applications International Corporation (SAIC) (NYSE: SAI ) ... National Institute of Allergy and Infectious Diseases (NIAID), part ... preclinical services for the development of biopharmaceutical products for ... the end of fiscal year 2011.  The total funding ...
... NEW YORK, Oct. 19, 2011 ... research report is available in its ... Erythematosus Therapeutics (SLE) - Pipeline Assessment ... http://www.reportlinker.com/p0656881/Systemic-Lupus-Erythematosus-Therapeutics-SLE---Pipeline-Assessment-and-Market-Forecasts-to-2018.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=Pathology ...
Cached Biology Technology:Endress+Hauser and Finesse Solutions Form Strategic Partnership - Swiss Process Automation Provider Invests in US Biotech Company 2Endress+Hauser and Finesse Solutions Form Strategic Partnership - Swiss Process Automation Provider Invests in US Biotech Company 3SAIC Awarded Contract by National Institute of Allergy and Infectious Diseases 2Systemic Lupus Erythematosus Therapeutics (SLE) - Pipeline Assessment and Market Forecasts to 2018 2Systemic Lupus Erythematosus Therapeutics (SLE) - Pipeline Assessment and Market Forecasts to 2018 3Systemic Lupus Erythematosus Therapeutics (SLE) - Pipeline Assessment and Market Forecasts to 2018 4Systemic Lupus Erythematosus Therapeutics (SLE) - Pipeline Assessment and Market Forecasts to 2018 5Systemic Lupus Erythematosus Therapeutics (SLE) - Pipeline Assessment and Market Forecasts to 2018 6Systemic Lupus Erythematosus Therapeutics (SLE) - Pipeline Assessment and Market Forecasts to 2018 7Systemic Lupus Erythematosus Therapeutics (SLE) - Pipeline Assessment and Market Forecasts to 2018 8Systemic Lupus Erythematosus Therapeutics (SLE) - Pipeline Assessment and Market Forecasts to 2018 9Systemic Lupus Erythematosus Therapeutics (SLE) - Pipeline Assessment and Market Forecasts to 2018 10
(Date:10/16/2014)... have a new synthesis of recent research findings to ... in the two states. , The Ecology and ... Washington: A Synthesis of the Relevant Biophysical Science and ... published by the U.S. Forest Service,s Pacific Northwest Research ... managers for a synthesis of the large body of ...
(Date:10/16/2014)... efficiently, they are anything but sustainable: environmental damage ... is becoming increasingly evident. Despite their disadvantages, however, ... regarded as the sole possibility of achieving higher ... Bernhard Schmid, an ecology professor at the University ... agriculture and forestry. After all, a new study ...
(Date:10/16/2014)... Calif. (October 16, 2014) – Post-menopausal women experienced ... on hormone levels or genital bleeding, after 12 ... an investigational fermented soy germ-based nutritional supplement previously ... to a new peer-reviewed pilot study reported in ... (NAMS) annual scientific meeting. , "These data ...
Breaking Biology News(10 mins):New report synthesizes best available science on management of moist mixed-conifer forests 2Plant communities produce greater yield than monocultures 2Plant communities produce greater yield than monocultures 3S-equol supplements associated with improved measures of reproductive health in postmenopausal women 2
... Virus (HCV) infects up to 500,000 people in the ... is the single biggest cause of people requiring a ... with groups across Europe and the USA, scientists from ... may be a significant step towards a vaccine. ...
... The Simons Foundation, through its Autism Research Initiative, has ... University Cell and DNA Repository (RUCDR) to establish a ... will be collected from 2,000 families that have a ... this project is known, will constitute the core resource ...
... may be to blame for the gradual extinction of ... according to Ulrich Kutschera and colleagues from the University ... in Austria. Their findings show that human-induced temperature ... of Austria may have led to the near extinction ...
Cached Biology News:Possible hepatitis C vaccine 2Rutgers Genetics receives $7.8 million for autism research 2Rutgers Genetics receives $7.8 million for autism research 3Role reversal as humans suck life out of leeches 2
1M stock solution (238mg/ml)...
...
Request Info...
... peptide derived from the C-terminal region catalytic ... C zeta isoform (PKCzeta). Specificity: Reacts ... Recognizes PKCzeta and PKMzeta (PKCzeta II) ... Reactivity: Mouse Rat (positive controls: mouse and ...
Biology Products: